Spcas9 HNH domain deletion for an improved RT editor

A Cas9 nickase with HNH domain deletions and linker truncations addresses unwanted indels and compactness issues, improving editing precision and enabling efficient delivery through AAV vectors.

WO2026236179A1PCT designated stage Publication Date: 2026-11-12VERTEX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026649
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing CRISPR-based gene editing systems, such as Prime Editing, face challenges with unwanted indels due to incomplete inactivation of the HNH domain in Cas9 nickases, and are too large to fit into single AAV vectors, necessitating more compact cargo for efficient delivery.

Method used

Engineering a Cas9 nickase with deletions in the HNH domain and optional linker truncations, retaining RuvC nickase activity, to enhance editing accuracy and compactness for viral vector packaging.

Benefits of technology

The modified Cas9 nickase achieves improved editing precision and fits within AAV vectors, enhancing the efficiency and accuracy of gene editing without causing double-strand breaks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026649_12112026_PF_FP_ABST
    Figure US2026026649_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to Cas9 endonucleases having deletions in the HNH domain, and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 67573-442235VP 1 / 24-010 WOSPCAS9 HNH DOMAIN DELETION FOR AN IMPROVED RT EDITOR RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 800,581 filed on May 6, 2025, which is incorporated by reference in its entirety herein.SEQUENCE

[0002] The Sequence Listing associated with this application is provided in XML format in lieu of paper copy, and is hereby incorporated by reference into the specification. The name of the XML file containing the Sequence Listing is “67573-416082_SeqListing” The XML file is 57.4 KB, was created on April 30, 2025, and is being submitted electronically, concurrent with the filing of this specification.FIELD

[0003] The present disclosure relates to Cas9 endonucleases having deletions in the HNH domain while retaining editing efficiency for improved packaging into viral vector systems, and methods of use.BACKGROUND

[0004] The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) gene editing system has revolutionized the ability to precisely target and change DNA. The system requires the interplay of a variety of components, including a Cas9 endonuclease protein and two RNA molecules: a CRISPR RNA (crRNA) that is complementary to a target sequence, and a transactivating CRISPR RNA (tracRNA) that pairs with the crRNA to form a guide RNA (gRNA). Together, the CRISPR system may insert or remove pieces of DNA from a target sequence.

[0005] Additionally, Prime Editing (PE) is a “search and replace” editing technology that allows for the precise modification of a DNA sequence, including insertions, deletions and substitutions, without the need for double-strand breaks. Prime editing includes two protein components: a Cas9 nickase fused to a Moloney murine leukemia virus (M-MLV) reverse transcriptase, as well as a prime editing guide RNA (pegRNA) made of a single guide RNA (sgRNA), a primer binding site and a reverse transcriptase template sequence. A Cas9 nickaseAttorney Docket No.: 67573-442235VP 1 / 24-010 WO may have either its HNH or RuvC nuclease domain catalytically inactivated, resulting in a Cas9 enzyme that can only cut one strand of targeted double-stranded DNA. Prime editing occurs through the nicking of the non-complementary genomic strand, using the fused Cas9 nickase and reverse transcriptase in complex with the pegRNA, followed by the synthesis of an edited DNA flap using the pegRNA template. The edited 3' flap is processed by endogenous cellular pathways to permanently copy the edited sequence to the non-edited strand. Prime editors may still suffer from unwanted indels if the HNH domain is not fully inactivated, allowing low level cutting to still occur, and producing double stranded breaks. Accordingly, there is still a need to improve accuracy of prime editing and removing the HNH domain fully may result in lower undesired indels.

[0006] Additionally, non-viral and viral vectors are commonly used for the delivery of gene editing systems. Vectors such as Adeno-associated vectors (AAVs) may be used to package genetic information encoding cargo such as primed editors (PEs). However, prime editors and the CRISPR system components are generally too large to fit into a single AAV. Accordingly, there is a need for more compact CRISPR-based cargo (e.g„ a Cas9 nickase) that may be encoded by a nucleic acid and encapsulated by a single AAV.BRIEF SUMMARY OF THE DISCLOSURE

[0007] One embodiment described herein is an engineered. Cas9 nickase comprising a deletion of one or more amino acid residues in an HNH domain comprising the amino acid sequence of SEQ ID NO. 12.

[0008] In one aspect, the deletion is about 70%, about 80%, about 90%, or about 95% of the HNH domain of SEQ ID NO. 12. In another aspect, the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids, or about 125 amino acids, or more from the HNH domain of SEQ ID NO. 12. In another aspect, the deletion is from about amino acid residues 1 to about 120, about amino acid residues 1 to about 129, about amino acid residues 3 to about 116, about amino acid residues 3 to about 120, about amino acid residues 14 to about 115, or about amino acid residues 17 to about 129 of SEQ ID NO. 12. In another aspect of the Cas9 nickase described herein, the entire HNH domain is removed.

[0009] In another aspect of the Cas9 nickase described herein, the Cas9 nickase is derived from Streptococcus pyogenes.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0010] In another aspect, the Cas9 nicksase comprises a first linker between the HNH domain and the RuvC II domain, wherein the first linker has an amino acid sequence of SEQ ID NO: 10. In one aspect, the first linker between the HNH domain and the RuvCII domain is truncated. In another aspect, the first linker truncation is at amino acid 12 or at amino acids 5 to 12 of SEQ ID NO: 10.

[0011] In another aspect, the Cas9 nickase comprises a second linker between the HNH domain and the RuvC III domain, said second linker having an amino acid sequence of SEQ ID NO: 11. In one aspect, the second linker between the HNH domain and the RuvC III domain is truncated. In another aspect, the second linker truncation is at amino acid 1 or at amino acids 1 to 13 of SEQ ID NO. 11.

[0012] In another aspect of the Cas9 nickase described herein the Cas9 retains RuvC nickase activity.

[0013] Another aspect described herein is a prime editor comprising the Cas9 as described herein, and a reverse transcriptase sequence. In one aspect, the reverse transcriptase is derived from Moloney Murine Leukemia virus. In another aspect, the prime editor comprises an amino acid sequence at least 80% identical to:(a) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGGGLSELDKAGFIKRQLVETRQI TKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAttorney Docket No.: 67573-442235VPV24-010 WO AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNF FKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF SKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKEL LGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGN ELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADA NLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNI EDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQL TWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRA LLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALG LPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAI AVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFG PVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEG QRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVK LD (SEQ ID NO: 2);(b) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKAttorney Docket No.: 67573-442235VPV24-010 WO TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYL NAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKT EITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKE SILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGIT IMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELA LPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANL DKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI HQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDE YRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMS QEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHP TVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWT RLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQT LGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFL GKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLT KPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVA LNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKA GAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIH GEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQ AARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD(SEQ ID NO: 3);(c) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKREAttorney Docket No.: 67573-442235VPV24-010 WO DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKITQRKFDNLTKAERGGLSELDKAGF IKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNI VKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRM LASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQI SEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK RYTSTKEVLDATLIHQSITGLYETRIDITQRLSQLGGDSGGSSGGSKRTADGSEFESPKKK RKVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAP LIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTND YRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPL FAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLL LAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEAR KETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKA YQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDP VAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMT HYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDA DHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEG KKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCP GHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKK KRKVGSGPAAKRVKLD (SEQ ID NO: 4);(d) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLAttorney Docket No.: 67573-442235VPV24-010 WO ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQI LDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILP KRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIME RSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPS KYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKV LSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRL HETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQE ARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTV PNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRL PQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLG NLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG KAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTK PFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTK DAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVAL NPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAG AAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHG EIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAAttorney Docket No.: 67573-442235VPV24-010 WO ARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 5);(e) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRTQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQIT KHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFF KTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGmMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADA NLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNI EDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQL TWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRA LLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALG LPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAttorney Docket No.: 67573-442235VPV24-010 WO AVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFG PVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEG QRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVK LD (SEQ ID NO: 6);(f) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRM NTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALI KKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIR KRPLIETNGETGEIVWDKGRDFATVRKVLS MPQ VNIVKKTEVQTGGFS KES ILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKN PIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLY LASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETR IDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRLHETSKEP DVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPH IQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLS GLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPAttorney Docket No.: 67573-442235VPV24-010 WO TLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRAS AKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLF IPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDE KQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTM GQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPL PEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTET EVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRG WLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAI TETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 7); or(g) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIRE VKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYG DYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEI VWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKK YGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGAttorney Docket No.: 67573-442235VP 1 / 24-010 WO GSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSD FPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVP CQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTV LDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDL ADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQV KYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPL YPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLT QKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHA VEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLD ILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAG TSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNK DEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENS SPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 8).

[0014] Another aspect described herein is a system comprising the prime editor as described herein, wherein the system further comprises a sgRNA. In one aspect, the system further comprises a pegRNA.

[0015] In another aspect described herein is a nucleic acid encoding the Cas9 nickase as described herein, or the prime editor as described herein. In one aspect, the nucleic acid is codon-optimized for expression in mammalian cells. In another aspect, the nucleic acid is codon-optimized for expression in human cells.

[0016] Another aspect described herein is a eukaryotic cell comprising the Cas9 nickase as described herein, the prime editor as described herein or the system as described herein. In one aspect of the eukaryotic cell, the cell is a human cell.

[0017] Another aspect as described herein is a method of cleaving a target nucleic acid in a eukaryotic cell comprising contacting the cell with the Cas9 nickase as described herein, or the prime editor as described herein, or the system as described herein; and wherein the Cas9 nickase, the prime editor or system is capable of causing a break in the target nucleic acid sequence. In another aspect, the break is single stranded break.

[0018] Another aspect described herein is a method of altering expression of a target nucleic acid in a eukaryotic cell comprising contacting the cell with the system as described herein; wherein the prime editor is capable of binding to and editing the target nucleic acid sequence.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0019] Another aspect described herein is a method of modifying a target nucleic acid in a eukaryotic cell comprising contacting the cell with the system as described herein; and wherein the prime editor is capable of binding to and editing the target nucleic acid sequence.

[0020] Another aspect described herein is a method as described herein, wherein the Cas9 is operably linked to a promoter sequence for expression in a eukaryotic cell, and wherein the reverse transcriptase is operably linked to a promoter sequence for expression in a eukaryotic cell. In one aspect, the eukaryotic cell is a human cell. In another aspect, the promoter sequence is a eukaryotic or viral promoter.

[0021] Another aspect described herein is a vector comprising the Cas9 as described herein, the prime editor as described herein or the system as described herein. In one aspect, the vector is a plasmid vector or a viral vector. In one aspect, the viral vector is an adeno associated virus (AAV) vector or a lentiviral vector.

[0022] Another aspect described herein is a method of treating a disorder or a disease in a subject in need thereof, the method comprising administering to the subject the system as described herein.

[0023] Another aspect described herein is a method of treating a disorder or a disease in a subject in need thereof, the method comprising administering to the subject a Cas9 nickase comprising a deletion of about 90 amino acids, about 100 amino acids, about 110 amino acids, or 120 amino acids, or more from an HNH domain comprising SEQ ID NO. 12. In some aspects, the deletion is about 70%. about 80%, about 90%, or about 95% of the HNH domain of SEQ ID NO.12. In another aspect, the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids, or about 125 amino acids, or more from the HNH domain of SEQ ID NO. 12. In yet another aspect the deletion is from about amino acid residues 1 to about 120, about amino acid residues 1 to about 129, about amino acid residues 3 to about 116, about amino acid residues 3 to about 120, about amino acid residues 14 to about 115, or about amino acid residues 17 to about 129 of SEQ ID NO. 12. In another aspect the entire HNH domain is removed.BRIEF DESCRIPTION OF THE FIGURES

[0024] Figure 1 is a diagram describing the domain organization of a Cas9 nickase.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0025] Figure 2 is Table A. describing sequences for the prime editing protein constructs described herein.

[0026] Figure 3 is a plot depicting the total percent editing for each prime editing construct characterized by whether the editing was (a) precise edit; (b) a precise edit plus another modification; or (c) an imprecise edit.DETAILED DESCRIPTION OF THE DISCLOSURE

[0027] The present disclosure is directed to Cas9 nickase enzymes having a deletion in the HNH domain, and methods of using such enzymes for gene editing and treating disease.

[0028] The following description and examples illustrate embodiments of the present disclosure in detail. It is to be understood that this disclosure is not limited to the particular embodiments described herein and as such can vary. Those of skill in the art will recognize that there are numerous variations and modifications of this disclosure, which are encompassed within its scope.

[0029] All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains.

[0030] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0031] Although various features of the present disclosure may be described in the context of a single embodiment, the features can also be provided separately as aspects of the embodiments and / or in any suitable combination. Conversely, although the present disclosure may be described herein in the context of separate embodiments for clarity, the present disclosure may also be implemented in a single embodiment.

[0032] The following definitions supplement those in the art and are directed to the present disclosure and are not to be imputed to any related or unrelated case, e.g., to any commonly owned patent or application. Although any methods and materials similar or equivalent to those described herein may be used in the practice for testing of the present disclosure, the preferred materials and methods are described herein. Accordingly, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0033] In the present disclosure, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

[0034] In the present disclosure, the use of “or” means “and / or” unless stated otherwise. The terms “and / or” and “any combination thereof’ and their grammatical equivalents as used herein, can be used interchangeably. These terms can convey that any combination is specifically contemplated. Solely for illustrative purposes, the following phrases “A, B, and / or C” or “A, B, C, or any combination thereof’ can mean “A individually; B individually; C individually; A and B; B and C; A and C; and A, B, and C.” The term “or” can be used conjunctively or disjunctively, unless the context specifically refers to a disjunctive use.

[0035] Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting.

[0036] Reference to “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures. Reference to “aspects,” “an aspect,” or “one aspect” refers to features of any embodiment.

[0037] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure.

[0038] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system.

[0039] As used herein, the term “edit,” “editing,” or “edited” refers to a method of altering a nucleic acid sequence of a polynucleotide (e.g., for example, a wild type naturally occurringAttorney Docket No.: 67573-442235VP 1 / 24-010 WO nucleic acid sequence or a mutated naturally occurring sequence) by selective modification (e.g., deletion, insertion, or substitution) of one or more nucleotides in a specific genomic target. Such a specific genomic target includes, but is not limited to, a chromosomal region, a gene, a promoter, an open reading frame or any nucleic acid sequence.

[0040] As used herein, the term “target” or “target site” refers to a pre-identified nucleic acid sequence of any composition and / or length. Such target sites include, but are not limited to, a chromosomal region, a gene, a promoter, an open reading frame or any nucleic acid sequence. In some embodiments, the present disclosure interrogates these specific genomic target sequences with complementary sequences of gRNA.

[0041] The term “effective amount” as used herein, refers to a particular amount of a pharmaceutical composition comprising a therapeutic agent that achieves a clinically beneficial result (i.e., for example, a reduction of symptoms). Toxicity and therapeutic efficacy of such compositions may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).

[0042] The term “pharmaceutically” or “pharmacologically acceptable”, as used herein, refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.

[0043] The term, “pharmaceutically acceptable carrier”, as used herein, includes any and all solvents, or a dispersion medium including, but not limited to, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be incorporated into such carriers.

[0044] The term “viral vector” encompasses any nucleic acid construct derived from a virus genome capable of incorporating heterologous nucleic acid sequences for expression in a host organism. For example, such viral vectors may include, but are not limited to, adeno-associated viral vectors, lentiviral vectors, SV40 viral vectors, retroviral vectors, or adenoviral vectors. Although viral vectors are occasionally created from pathogenic viruses, they may be modified in such a way as to minimize their overall health risk. In some embodiments, this involves the deletion of a part of the viral genome involved with viral replication. Such a virus can efficiently infectAttorney Docket No.: 67573-442235VP 1 / 24-010 WO cells but, once the infection has taken place, the virus may require a helper virus to provide the missing proteins for production of new virions. Preferably, viral vectors should have a minimal effect on the physiology of the cell it infects and exhibit genetically stable properties (e.g., do not undergo spontaneous genome rearrangement). Most viral vectors are engineered to infect as wide a range of cell types as possible. Even so, a viral receptor may be modified to target the virus to a specific kind of cell. Viruses modified in this manner are said to be pseudotyped. Viral vectors are often engineered to incorporate certain genes that help identify which cells took up the viral genes. These genes are called marker genes. For example, a common marker gene confers antibiotic resistance to a certain antibiotic.

[0045] As used herein, the term “Cas9” refers to a protein derived from Type II CRISPR systems. In some embodiments, a Cas9 is an enzyme that is specialized for generating doublestrand breaks in DNA, with two active cutting sites (the HNH and RuvC domains), one for each strand of the double helix. In other embodiments, the Cas9 nickase protein lacks the ability to cut both strands of DNA, i.e., it is a nickase. In some embodiments, to generate the nickase, the Cas9 has one or more amino acid modifications in the HNH nuclease domain. In some aspects, the modifications may be either a deletion of one or more amino acids, or a mutation of one or more amino acids. In some embodiments, to generate the nickase, the Cas9 has one or more amino acid deletions in the HNH nuclease domain. In some embodiments, to generate the nickase, the Cas9 has one or more amino acid mutations in HNH nuclease domain.

[0046] In some embodiments, the Cas9 nickase proteins disclosed herein are capable of binding to DNA (e.g., when complexed with a sgRNA). In some embodiments, tracrRNA and spacer RNA have been combined into a “single-guide RNA” (sgRNA) molecule that, when codelivered with Cas9. may find and cleave DNA targets through Watson-Crick pairing between the guide sequence within the sgRNA and the target DNA sequence. Jinek et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity” Science 337(6096):816-821 (2012), incorporated by reference with regard to such background teaching only.

[0047] In some embodiments, the Cas9 nickase protein may be co-delivered with a heterologous moiety, (e.g., a reverse transcriptase). In some embodiments, the heterologous moiety is a protein useful for gene editing (e.g., Moloney murine leukemia virus (MMLV) reverse transcriptase (RT).Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0048] The term “protospacer adjacent motif’ (or PAM) as used herein, refers to a DNA sequence that may be required for a Cas9 / sgRNA to form an R-loop to interrogate a specific DNA sequence through Watson-Crick pairing of its guide RNA with the genome. The PAM specificity may be a function of the DNA-binding specificity of the Cas9 nickase protein (e.g.. a “protospacer adjacent motif recognition domain” at the C-terminus of Cas9).

[0049] “Guide RNA”, “gRNA”, and simply “guide”, are used herein interchangeably to refer to either a crRNA (also known as CRISPR RNA), or the combination of a crRNA and a trRNA (also known as tracrRNA). The crRNA and trRNA may be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). “Guide RNA” refers to each type. The trRNA may be a naturally occurring sequence, or a trRNA sequence with modifications or variations compared to naturally occurring sequences.

[0050] For clarity, the terms “guide RNA” or “guide” as used herein, and unless specifically stated otherwise, may refer to an RNA molecule (comprising A, C, G, and U nucleotides) or to a DNA molecule encoding such an RNA molecule (comprising A, C, G, and T nucleotides) or complementary sequences thereof. In general, in the case of a DNA nucleic acid construct encoding a guide RNA, the U residues in any of the RNA sequences described herein may be replaced with T residues, and in the case of a guide RNA construct encoded by any of the DNA sequences described herein, the T residues may be replaced with U residues.

[0051] As used herein, the term “sgRNA” refers to single guide RNA used in conjunction with CRISPR associated systems (Cas). sgRNAs are a fusion of crRNA and tracrRNA and contain nucleotides of sequence complementary to the desired target site. Watson-Crick pairing of the sgRNA with the target site permits R-loop formation, which in conjunction with a functional PAM permits DNA cleavage or in the case of nuclease-deficient Cas9 allows binds to the DNA at that locus. In some aspects, the sgRNA may be an “ngRNA”, referred to herein as a nicking sgRNA.

[0052] The term “prime editing guide RNA”, or “PegRNA”, refers to a guide polynucleotide that comprises one or more intended nucleotide edits (i.e., one or more nucleotide changes) for incorporation into the target DNA. In some embodiments, the PegRNA associates with and directs a prime editor to incorporate the one or more intended nucleotide edits into the target gene via prime editing. “Precise edit” or “intended nucleotide edit” refers to a specified deletion of one or more nucleotides at one specific position, insertion of one or more nucleotides at one specific position, substitution of a single nucleotide, or other alterations at one specific position to beAttorney Docket No.: 67573-442235VPI / 24-010 WO incorporated into the sequence of the target gene. Intended nucleotide edit may refer to the edit on the editing template as compared to the sequence on the target strand of the target gene, or may refer to the edit encoded by the editing template on the newly synthesized single stranded DNA that replaces the editing target sequence, as compared to the editing target sequence. An “imprecise edit” refers to an unintended or undesired deletion or alteration at any position or no editing is performed. In some aspects, a PegRNA comprises a spacer sequence that is complementary or substantially complementary to a search target sequence on a target strand of the target gene. In some aspects, the PegRNA comprises a gRNA core that associates with a DNA binding domain, e.g., a CRISPR-Cas protein domain, of a prime editor. In some embodiments, the PegRNA further comprises an extended nucleotide sequence comprising one or more intended nucleotide edits compared to the endogenous sequence of the target gene, wherein the extended nucleotide sequence may be referred to as an extension arm.

[0053] As used herein, a “spacer sequence,” sometimes also referred to herein and in the literature as a “spacer,” “protospacer,” “guide sequence,” or “targeting sequence” refers to a sequence within a guide RNA that is complementary to a target sequence and functions to direct a guide RNA to a target sequence for cleavage by a Cas9. For clarity, the terms “spacer sequence”, “spacer,” “protospacer,” “guide sequence,” or “targeting sequence” as used herein, and unless specifically stated otherwise, may refer to an RNA molecule (comprising A, C, G, and U nucleotides) or to a DNA molecule encoding such an RNA molecule (comprising A, C, G, and T nucleotides) or complementary sequences thereof.

[0054] “Nucleic acid sequence”, “polynucleotide sequence”, and “nucleotide sequence” as used herein refer to an oligonucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double- stranded, and represent the sense or antisense strand.

[0055] The term “an isolated nucleic acid”, as used herein, refers to any nucleic acid molecule that has been removed from its natural state (e.g., removed from a cell and is. in a preferred embodiment, free of other genomic nucleic acid).

[0056] The terms “amino acid sequence” and “polypeptide sequence” as used herein, are interchangeable and refer to a sequence of amino acids.

[0057] As used herein the term “portion” when in reference to a protein (as in “a portion of a given protein”) refers to fragments of that protein. Unless specified otherwise, the fragments mayAttorney Docket No.: 67573-442235VP 1 / 24-010 WO range in size from three amino acid residues to the entire amino acid sequence minus one amino acid.

[0058] The term “portion” when used in reference to a nucleotide sequence refers to fragments of that nucleotide sequence. Unless specified otherwise, the fragments may range in size from 5 nucleotide residues to the entire nucleotide sequence minus one nucleic acid residue.

[0059] As used herein, the terms “complementary” or “complementarity” are used in reference to “polynucleotides” and “oligonucleotides” (which are interchangeable terms that refer to a sequence of nucleotides) related by the base-pairing rules. For example, the sequence “C-A-G-T,” is complementary to the sequence “G-T-C-A.” Complementarity can be “partial” or “total.” “Partial” complementarity is where one or more nucleic acid bases is not matched according to the base pairing rules. “Total” or “complete” complementarity between nucleic acids is where each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.

[0060] The terms “homology” and “homologous” as used herein in reference to nucleotide sequences refer to a degree of complementarity with other nucleotide sequences. There may be partial homology or complete homology (i.e., identity). A nucleotide sequence which is partially complementary, i.e., “substantially homologous,” to a nucleic acid sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid sequence. The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence to a target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity);Attorney Docket No.: 67573-442235VP 1 / 24-010 WO in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.

[0061] The terms “homology” and “homologous” as used herein in reference to amino acid sequences refer to the degree of identity of the primary structure between two amino acid sequences. Such a degree of identity may be directed to a portion of each amino acid sequence, or to the entire length of the amino acid sequence. Two or more amino acid sequences that are “substantially homologous” may have at least 75% identity, at least 85% identity, at least 95%, or 100% identity.

[0062] An oligonucleotide sequence which is a “homolog” is defined herein as an oligonucleotide sequence which exhibits greater than or equal to 50% identity to a sequence, when sequences having a length of 100 bp or larger are compared.

[0063] DNA and RNA molecules are said to have “5' ends” and “3' ends” because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage. Therefore, an end of an oligonucleotide is referred to as the “5' end” if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring. An end of an oligonucleotide is referred to as the “3' end” if its 3' oxygen is not linked to a 5' phosphate of another mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also may be said to have 5' and 3' ends. In either a linear or circular DNA or RNA molecule, discrete elements are referred to as being upstream” or 5' of the “downstream” or 3' elements. This terminology reflects the fact that transcription proceeds in a 5’ to 3' fashion along the DNA or RNA strand. The promoter and enhancer elements which direct transcription of a linked gene are generally located 5’ or upstream of the coding region. However, enhancer elements can exert their effect even when located 3' of the promoter element and the coding region. Transcription termination and polyadenylation signals are located 3' or downstream of the coding region.

[0064] The term “transfection” or “transfected” refers to the introduction of foreign DNA or RNA into a cell.

[0065] As used herein, the terms “nucleic acid molecule encoding”, “DNA (or RNA) sequence encoding,” and “DNA (or RNA) encoding” refer to the order or sequence of nucleotides along a strand of nucleic acid. The order of these deoxyribonucleotides determines the order of aminoAttorney Docket No.: 67573-442235VP 1 / 24-010 WO acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.

[0066] In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences which are present on the RNA transcript. These sequences are referred to as “flanking” sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers which control or influence the transcription of the gene. The 3' flanking region may contain sequences which direct the termination of transcription, posttranscriptional cleavage and polyadenylation.

[0067] The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.

[0068] The terms “patient,” “subject,” and “individual” may be used interchangeably and refer to either a human or a non-human animal. The “non-human animals” and “non-human mammals” as used interchangeably herein, includes mammals such as rats, mice, rabbits, sheep, cats, dogs, cows, pigs, and non-human primates. The term “subject” also encompasses any vertebrate including but not limited to mammals, reptiles, amphibians and fish. However, advantageously, the subject is a mammal such as a human, or other mammals such as a domesticated mammal, e.g., dog, cat, horse, and the like, or production mammal, e.g. cow, sheep, pig, and the like. “Patient in need thereof’ or “subject in need thereof’ is referred to herein as a patient diagnosed with or suspected of having a disease or disorder, for instance, but not restricted to cancer.

[0069] The term “treatment” or “treating” refers to preventing or delaying the onset, slowing down the progression, and / or or ameliorating the symptoms of the disorder. In some embodiments, any of the proteins disclosed herein (e.g.. any of the Cas9 nickase or prime editors disclosed herein) may be administered to a subject. In some embodiments, the subject has a disease.

[0070] The term “genetically engineered” and its grammatical equivalents as used herein refer to a non-naturally occurring genetic modification. Examples of genetic engineering include use of gene editing systems such as the CRISPR / Cas, the TALEN, and / or zinc finger systems for disrupting the expression e.g., to reduce or eliminate expression) of one or more gene targets in aAttorney Docket No.: 67573-442235VP 1 / 24-010 WO cell, or for increasing the expression (e.g., by inserting a gene of interest) into a cell. A “genetically engineered” cell, as used herein, means a cell that was genetically engineered, or a cell that was derived and / or descended from a cell that was genetically engineered.

[0071] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0. 6.1, 6.2, 6.3. 6.4, 6.5. 6.6, 6.7, 6.8. 6.9, and 7.0 are explicitly contemplated.

[0072] The CRISPR-Cas9 based gene editing system is widely used to modify genomic DNA at a specific target site for the purpose of gene silencing, correction of mutations, and the acquisition of novel genetic traits. The components of the CRISPR-Cas9 system include a Cas9 endonuclease and a single-guide RNA (sgRNA) composed of a crRNA spacer sequence that is complementary to a target DNA sequence, and a scaffold tracrRNA sequence that binds the crRNA and guides the sgRNA to Cas9. Together the Cas9-sgRNA form a ribonucleoprotein (RNP) complex that finds, binds and cleaves a specific DNA target site. Recognition of a protospacer adjacent motif (PAM) adjacent to the target sequence allows Cas9 to bind to the target DNA and make a double stranded cut at the target site. Thus, portions of target DNA could be modified through insertions and / or deletions (i.e. indels) from the genome using the CRISPR-Cas9 system. These systems are known in art, as described in, for example, Asmamaw et al., (2021). Collectively, the various components of the CRISPR-Cas9 technology, i.e. the Cas9 protein, the various guide RNAs and their RNA components, constitute a “system” and are referred to as such herein.

[0073] Various permutations of the CRISPR-Cas9 system have evolved using Cas9 variants to allow for more precise gene editing, without the use of double stranded breaks (DBS) and the resulting off-target effects. Prime editing is a gene editing technique based on CRISPR / Cas9 that allows for specific targeted insertions, deletions and / or base substitutions without doublestrand breaks, using a mutated Cas9 in the form of a Cas9 nickase, modified to only make single strand DNA cuts. The Cas9 nickase may be further co-expressed with a reverse transcriptase and subsequently complexed with a sgRNA or a prime editing guide RNA (pegRNA). Once the Cas9 nickase cleaves a single strand of DNA at the target site, the reverse transcriptase uses the pegRNA as a template for reverse transcription, and new genetic information may be “written” into the DNA at the target site (See, for example, Yan et al., (2020)). Thus, because primeAttorney Docket No.: 67573-442235VP 1 / 24-010 WO editing requires two proteins the nucleic acid construct needed for this gene editing technique may generally be too large to fit into a single vector for delivery See, for example, Davis et al., (2023). Without being bound by any theory, it is believed that the HNH domain is required for RuvC nuclease domain activation but is dispensable for RNA-guided DNA targeting, making the HNH domain an attractive target for deletions to reduce the overall size of the Cas9 nickase protein.

[0074] Thus, the present disclosure describes an engineered Cas9 nickase comprising a deletion of one or more amino acids in an HNH domain, and methods of using such nickases for altering expression of, or modifying, a target nucleic acid, or treating a disorder or disease.

[0075] Wild-type Cas9 nickase protein possess two lobes, the REC lobe responsible for binding guide RNA, and the NUC lobe, responsible for cutting it. Specifically, the NUC lobe comprises two domains responsible for cutting the DNA: the HNH domain which cleaves the complementary strand of the target DNA sequence; and the RuvC strand which cleaves the non-complementary strand. Figure 1 describes the domain organization of a Cas9 nucleic acid construct, made of about 1368 (AA) in length. The HNH domain, excluding LI and L2, is defined by the amino acid sequence of SEQ ID NO. 12 and is 129 amino acids long:SRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQ ELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVV KKMKNYWRQLLNAKLITQRKFDNLTKAER(SEQ ID NO. 12).

[0076] Linker sequences on either side of the HNH domain link it to the RuvC domain, defined as Linker 1 (LI), having an amino acid sequence of SEQ ID NO: 10:RENQTTQKGQKN and located upstream of the HNH domain; and Linker 2 (L2), having an amino acid sequence of SEQ ID NO: 11: GGLSELDKAGFIKRQLVE is located downstream of the HNH domain.

[0077] In another aspect, the engineered Cas9 nickase described herein comprises a linker between the HNH domain and the RuvCII domain. In another aspect, the linker comprises an amino acid sequence of SEQ ID NO. 10. In other aspects, the engineered Cas9 nickase described herein comprises a linker between the HNH domain and the RuvCIII domain. In another aspect, the linker comprises an amino acid sequence of SEQ ID NO. 11.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0078] One embodiment described herein is an engineered Cas9 nickase comprising a deletion of one or more amino acids in an HNH domain.

[0079] In some aspects, the Cas9 nickase may be from Streptococcus pyogenes or Streptococcus thermophiles. Additional Cas9 nickase species may be obtained and used herein include: Acidovorax avenae, Actinobacillus pleuropneumoniae , Actinobacillus succinogenes, Actinobacillus suis, Actinomyces sp., Alicy cliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus', Bacillus smithii. Bacillus thuringiensis, Bacteroides sp., Blastopirellula marina. Bradyrhizobium sp., Brevibacillus laterosporus, Campylobacter coli, Campylobacter jejuni, Campylobacter lari, Candidates Puniceispirillum, Clostridium cellulolylicum, Clostridium perfingens, Corynebacterium accolens, Corynebacterium dolichum, Corynebacterium matruchotii, Dinoroseobacter shibae, Eubacterium dolichum, gamma proteobacterium, Gluconacetobacter diazotrophicus, Haemoplzilus parainfluenzae, Haemophilus sputorum, Helicobacter canadensis, Helicohacter cinaedi, Helicobacter mustelae, llyobacter polytropus, Kingella kingae, lactobacillus crispatus, listeria ivanovii, listeria monocytogenes, listeriaceae bacterium, Methylocystis ^.,Methylosinus trichosporium, Mobiluncus mulieris, Neisseria bacilliformis , Neisseria cinerea, Neisseria flavescens, Neisseria lactamica, Neisseria sp., Neisseria wadsworthii, Nitrosomonas sp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinatutells, Ralstonia syzygii, Rhodopseudomonas palustris, Rhodovulum sp., Simonsiella muelleri, Sphingomonas sp., Sporolactobacillus vineae, Staphylococcus lugdunensis, Streptococcus sp., Subdoligranulum sp., Tistrella mobilis, Treponema sp., or Verminephrobacter eiseniae. In one aspect, any of the Cas9 nickase proteins described herein may be derived from Streptococcus pyogenes.

[0080] In one aspect of the engineered Cas9 nickase proteins described herein, one or more amino acid residues of the HNH domain of SEQ ID NO. 12 are deleted. Thus, HNH domain mutants are contemplated herein. In other aspects, specific residues from within the HNH sequence may be deleted or modified.

[0081] In some aspects of the engineered Cas9 nickase described herein, the deletions are from amino acid residues between the N-terminal portion and C-terminal portion of SEQ ID NO.12. In some aspects, the C-terminal portion of the amino acids sequence of SEQ ID NO. 12 is retained. In some aspects, retained amino acid residues of the C-terminal portion comprise from about residue 100 to about residue 129. In other aspect, the retained amino acid residues of theAttorney Docket No.: 67573-442235VP 1 / 24-010 WO C-terminal portion comprise from about residue 111 to about residue 129, from about 112 to about residue 129, from about 113 to about residue 129, from about 114 to about residue 129, from about 115 to about residue 129, from about 116 to about residue 129, from about 117 to about residue 129, from about 118 to about residue 129, from about 119 to about residue 129, from about 120 to about residue 129, from about 121 to about residue 129, from about 122 to about residue 129, from about 123 to about residue 129, from about 124 to about residue 129, from about 125 to about residue 129. from about 126 to about residue 129, from about 127 to about residue 129, from about 128 to about residue 129, from about 126 to about residue 129, or from about 128 to about residue 129.

[0082] In other aspects of the engineered Cas9 nickase described herein, the N-terminal portion of the amino acid sequence of SEQ ID NO. 12 is retained. In some aspects, retained amino acid residues of the N-terminal portion of SEQ ID NO. 12 comprise from about residue 1 to about residue 20, from about residue 1 to about residue 19, from about residue 1 to about residue 18, from about residue 1 to about residue 17, from about residue 1 to about residue 16, from about residue 1 to about residue 15, from about residue 1 to about residue 14, from about residue 1 to about residue 13, from about residue 1 to about residue 12, from about residue 1 to about residue 11. from about residue 1 to about residue 10, from about residue 1 to about residue 9, from about residue 1 to about residue 8, from about residue 1 to about residue 7, from about residue 1 to about residue 6, from about residue 1 to about residue 5, from about residue 1 to about residue 4, from about residue 1 to about residue 3, or from about residue 1 to about residue 2.

[0083] Any of the N-terminal deletions of the amino acid sequence of SEQ ID NO. 12 described herein may be combined with any of the C-terminal deletions of SEQ ID NO. 12 described herein.

[0084] In other aspects of the engineered Cas9 nickase described herein, the total number of deleted amino acid residues from the amino acid sequence of SEQ ID NO. 12 are from about 1 to about 128 residues, from about 1 to about 125 residues, from about 1 to about 120 residues, from about 1 to about 114 residues, from about 1 to about 110 residues, from about 1 to about 102 residues, from about 10 to about 128 residues, from about 113 to about 128 residues, from about 117 to about 128 residues, from about 1 to about 127 residues, from about 1 to about 117Attorney Docket No.: 67573-442235VP 1 / 24-010 WO residues, from about 1 to about 112 residues, from about 10 to about 120 residues, or from about 13 to about 125 residues.

[0085] In some aspects, the deletion removes about 128 amino acid residues, about 127 amino acid residues, about 126 amino acid residues, about 125 amino acid residues, about 124 amino acid residues, about 123 amino acid residues, about 122 amino acid residues, about 121 amino acid residues, about 120 amino acid residues, about 119 amino acid residues, about 118 amino acid residues, about 117 amino acid residues, about 116 amino acid residues, about 115 amino acid residues, about 114 amino acid residues, about 113 amino acid residues, about 112 amino acid residues, about 111 amino acid residues, about 110 amino acid residues, about 108 amino acid residues, about 107 amino acid residues, about 106 amino acid residues, about 105 amino acid residues, about 104 amino acid residues, about 102 amino acid residues, about 101 amino acid residues, about 100 amino acid residues, about 99 amino acid residues, about 98 amino acid residues, about 97 amino acid residues, about 96 amino acid residues, about 94 amino acid residues, about 95 amino acid residues, about 94 amino acid residues, about 93 amino acid residues, about 92 amino acid residues, about 91 amino acid residues, about 90 amino acid residues, about 89 amino acid residues, or about 88 amino acid residues of the sequence of SEQ ID NO. 12. In one aspect, the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids or about 120 amino acids, or more from the HNH domain of SEQ ID NO.12.

[0086] In other aspects of the engineered Cas9 nickase described herein, about 60% to about 99% of the amino acid sequence of SEQ ID NO. 12 is deleted. In some aspects, about 65% to about 95% of the amino acid sequence of SEQ ID NO. 12 is deleted. In some aspects, about 70% to about 90% of the amino acid sequence of SEQ ID NO. 12 is deleted. In some aspects, about 75% to about 85% of the amino acid sequence of SEQ ID NO. 12 is deleted. In other aspects, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%. about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%. about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100% of the amino acid sequence of SEQ ID NO. 12 is deleted. In one aspect,Attorney Docket No.: 67573-442235VP 1 / 24-010 WO the deletion is about 70%. about 80%, about 90% or about 95% of the HNH domain of SEQ ID NO. 12.

[0087] In some aspects of the engineered Cas9 nickase protein described herein, the deletion removes amino acid residues from about amino acid 1 to about amino acid 120 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 3 to about amino acid 129 of the sequence of SEQ ID NO. 12. In some aspects, the deletion removes amino acid residues from about amino acid 3 to about amino acid 120 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 12 to about amino acid 120 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 15 to about amino acid 129 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 17 to about amino acid 129 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 3 to about amino acid 119 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 14 to about amino acid 115 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 1 to about amino acid 119 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 3 to about amino acid 116 of the sequence of SEQ ID NO. 12. In other aspects, the deletion removes amino acid residues from about amino acid 3 to about amino acid 127 of the sequence of SEQ ID NO. 12.

[0088] In another aspect, the entire HNH domain is removed. In another aspect amino acids 1 - 129 are deleted from SEQ ID NO. 12. In another aspect 100% of SEQ ID NO. 12 is deleted. Linker mutants

[0089] In other aspects of the engineered Cas9 nickase described herein, Linker 1 (LI) or Linker 2 (L2) may be modified to delete one or more amino acid residues. In some aspects, the deletions may be a truncation off the N or C-terminal end of the linker sequence. In other aspects, specific residues from within the linker sequence may be deleted or modified.

[0090] In some aspects of the engineered Cas9 nickase described herein, the Linker 1 deletions are from amino acid residues between the N-terminal portion and C-terminal portion of SEQ ID NO. 10. In some aspects, the N-terminal portion of the amino acids sequence of SEQ ID NO. 10 is retained. In some aspects of the Linker 1, retained amino acid residues of the N-Attorney Docket No.: 67573-442235VP 1 / 24-010 WO terminal portion comprise from about residue 1 to about residue 4. In some aspects of the Linker 1, a truncation, deletion or modification may delete 1 amino acid residue, 2 amino acid residues, 3 amino acid residues, 4 amino acid residues, 5 amino acid residues, 6 amino acid residues, 7 amino acid residues. 8 amino acid residues or more. In other aspects of the Linker 1, the deletion removes about 1 to about 8 amino acid residues of the amino acid sequence of SEQ ID NO. 10.

[0091] In other aspects of the engineered Cas9 nickase described herein, the total number of deleted amino acid residues from the Linker 1 amino acid sequence of SEQ ID NO. 10 are from about 1 to about 11 residues, from about 1 to about 10 residues, from about 1 to about 9 residues, from about 1 to about 8 residues, from about 1 to about 7 residues, from about 1 to about 6 residues, from about 1 to about 5 residues, from about 1 to about 4 residues, from about 1 to about 3 residues, or from about 1 to about 2 residues.

[0092] In other aspects of the engineered Cas9 nickase described herein, about 8% to about 75% of the amino acid sequence of SEQ ID NO. 10 is deleted. In some aspects, about 8% to about 67% of the amino acid sequence of SEQ ID NO. 10 is deleted. In other aspects, about 8%, about 16%. about 17%, about 25%, about 33%, about 41%, about 42%, about 50%, about 58%, about 66%, about 67%, about 75%, about 83%, about 91%, about 92%, about 100% of the amino acid sequence of SEQ ID NO. 10 is deleted. In one aspect, the deletion is about 8%, about 50%, about 58% or about 67% of the LI domain of SEQ ID NO. 10.

[0093] In some aspects of the engineered Cas9 nickase protein described herein, the Linker 1 deletion removes amino acid residues from about amino acid 5 to about amino acid 12 of the sequence of SEQ ID NO. 10. In other aspects, the deletion removes amino acid residues from about amino acid 10 to about amino acid 12 of the sequence of SEQ ID NO. 10. In other aspects, the deletion removes amino acid residues from about amino acid 11 to about amino acid 12 of the sequence of SEQ ID NO. 10 In some aspects of the engineered Cas9 nickase protein described herein, the deletion removes from about amino acid 3 to about amino acid 12 of the sequence of SEQ ID NO. 10. amino acid residues 10.

[0094] In some aspects of the engineered Cas9 nickase described herein, the Linker 2 deletions are from amino acid residues between the N-terminal portion and C-terminal portion of SEQ ID NO. 11. In some aspects, the C-terminal portion of the amino acids sequence of SEQ ID NO. 11 is retained. In some aspects, retained amino acid residues of the C-terminal portion comprise from about residue 1 to about residue 5. In some aspects, a truncation, deletion orAttorney Docket No.: 67573-442235VP 1 / 24-010 WO modification may delete 1 amino acid residue, 2 amino acid residues, 3 amino acid residues, 4 amino acid residues, 5 amino acid residues, 6 amino acid residues, 7 amino acid residues, 8 amino acid residues, 9 amino acid residues, 10 amino acid residues, 11 amino acid residues, 12 amino acid residues. 13 amino acid residues or more. In other aspects, the deletion removes about 1 to about 13 amino acid residues of the amino acid sequence of SEQ ID NO. 11.

[0095] In other aspects of the engineered Cas9 nickase described herein, the total number of deleted amino acid residues from the Linker 2 amino acid sequence of SEQ ID NO. 11 are from about 1 to about 17 residues, from about 1 to about 16 residues, from about 1 to about 15 residues, from about 1 to about 14 residues, from about 1 to about 13 residues, from about 1 to about 12 residues, from about 1 to about 11 residues, from about 1 to about 10 residues, from about 1 to about 9 residues, from about 1 to about 8 residues, from about 1 to about 7 residues, from about 1 to about 6 residues, from about 1 to about 5 residues, from about 1 to about 4 residues, from about 1 to about 3 residues, or from about 1 to about 2 residues.

[0096] In other aspects of the engineered Cas9 nickase described herein, about 5% to about 75% of the Linker 2 amino acid sequence of SEQ ID NO. 11 is deleted. In some aspects, about 6% to about 72% of the amino acid sequence of SEQ ID NO. 11 is deleted. In other aspects, about 6%, about 11%, about 16%, about 17%, about 22%, about 27%, about 28%, about 33%, about 38%, about 39%, about 44%, about 50%, about 55%, about 56%, about 61%, about 66%, about 67%, about 72%, about 77%, about 78%, about 83%, about 88%, about 89%, about 94%, about 110% of the amino acid sequence of SEQ ID NO. 11 is deleted. In one aspect, the deletion is about 6%, about 50%, about 72% or about 77% of the L2 domain of SEQ ID NO. 12.

[0097] In some aspects of the engineered Cas9 nickase protein described herein, the deletion removes amino acid residues from about amino acid 1 to about amino acid 5 of the sequence of SEQ ID NO. 11. In other aspects, the deletion removes amino acid residues from about amino acid 1 to about amino acid 17 of the sequence of SEQ ID NO. 11. In some aspects of the engineered Cas9 nickase protein described herein, the deletion removes amino acid residues from about amino acid 1 to about amino acid 14 of the sequence of SEQ ID NO. 11. In some aspects of the engineered Cas9 nickase protein described herein, the deletion removes amino acid residues from about amino acid 1 to about amino acid 13 of the sequence of SEQ ID NO. 11.Attorney Docket No.: 67573-442235VPI / 24-010 WO

[0098] Any of the Linker 1 or Linker 2 sequences described herein, whether wild-type or modified to delete or change one or more residues, may be combined with any of HNH mutants described herein.

[0099] In some aspects, the Linker 1 amino acid sequence of SEQ ID NO: 10 may be entirely deleted, while the HNH amino acid sequence and / or the Linker 2 amino acid sequence remain. In other aspects, the Linker 2 amino acid sequence of SEQ ID NO: 11 may be entirely deleted, while the HNH amino acid sequence and / or the Linker 1 amino acid sequence remain. CAS length

[0100] In another aspect of the engineered Cas9 nickase protein described herein, the full length amino acid sequence of the Cas9 nickase is from about 1200 amino acids to about 1367 amino acids, from about 1240 amino acids to about 1350 amino acids, from about 1250 amino acids to about 1300 amino acids, about 1229 amino acids, about 1210 amino acids, about 1224 amino acids, about 1237 amino acids, about 1242 amino acids, about 1247 amino acids, about 1250 amino acids, about 1254 amino acids, about 1267 amino acids, about 1269 amino acids, about 1278 amino acids, about 1284 amino acids, about 1294 amino acids or about 1284 amino acids in length.

[0101] Any of the engineered Cas9 nickase proteins described herein may be encoded by a nucleic acid sequence. In another aspect described herein, nucleic acid sequences encoding any of the proteins described herein may be codon-optimized for expression in mammalian cells and specifically for expression in human cells. In one aspect, the Cas9 nickase nucleic acid sequence may be further engineered to be operably linked to another sequence for assembly of a nucleic acid construct. In some aspects, the Cas9 nickase protein may be operably linked to a promoter sequence for expression in a eukaryotic cell. In other aspects, the Cas9 nickase protein may be operably linked to a promoter sequence for expression in a viral cell. In some aspects, the promoter may be a eukaryotic or viral promoter. Commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. Other promoters can include, for example, EFl promoter, or EFl alpha promoter. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed„ Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. Any suitable promoter is contemplated herein.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0102] In other aspects, the Cas9 nickase proteins described herein may be operably linked to one or more nuclear localization signal sequence (NLSs) for transport of the expressed protein into the nucleus. In one aspect any of the nucleic acid sequences may encode an NLS sequence having an amino acid sequence of MKRTADGSEFESPKKKRKV (SEQ ID NO. 43), SGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGS (SEQ ID NO. 44), or SPKKKRKVGSGPAAKRVKLD (SEQ ID NO. 45). Any suitable NLS is contemplated herein. Thus, in another aspect described herein, the Cas9 nickase protein may be operably linked to one or more nuclear localization sequence.

[0103] In addition to Cas9, prime editing requires the use of a reverse transcriptase. In some aspects, the Cas9 nickase protein may be co-delivered with a reverse transcriptase. In another aspect of the engineered Cas9 nickase protein described herein, reverse transcriptase is operably linked to the Cas9 to form a “Cas9 nickase - reverse transcriptase” fusion protein, or “prime editor”. Reverse transcriptase may be fused at the C-terminus of the Cas9 nickase. Exemplary reverse transcriptase proteins include, but are not limited to, a Moloney murine leukemia virus derived reverse transcriptase (MMLV-RT) having the amino acid sequence of SEQ ID NO. 46:TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP LKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVK KPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDL KDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNE ALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLG YRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQ ALLTAP ALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKK LDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQP PDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCL DILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETE VIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIH GEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAE ARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFE(SEQ ID NO. 46).Attorney Docket No.: 67573-442235VP 1 / 24-010 WO Because two proteins may be encoded into the same nucleic acid construct, one or more promoters, regulatory elements, nuclear localization sequences, and / or self cleaving sequences may be engineered into a single nucleic acid construct, for separate expression of each protein.

[0104] Accordingly, in another aspect described herein, the nucleic acid sequence of any of the Cas9 nickase proteins described herein may be operably linked to a nucleic acid sequence encoding an amino acid sequence for a reverse transcriptase. In another aspect, the nucleic acid sequence the Cas9 nickase protein described herein may be operably linked to a nucleic acid sequence encoding an amino acid sequence for a Moloney murine leukemia virus derived reverse transcriptase (MMLV-RT). In yet another aspect, the nucleic acid sequence of any of the Cas9 nickase proteins described herein may be operably linked to a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO. 46.

[0105] Another aspect described herein is a fusion protein comprising any of the Cas9 nickase proteins described herein and a reverse transcriptase. In some aspects, the reverse transcriptase is a Moloney murine leukemia virus derived reverse transcriptase (MMLV-RT). In other aspects, the reverse transcriptase comprises the amino acid sequence of SEQ ID NO. 46. As used herein the term “fusion protein” is interchangeable with the term “prime editor” both of which refer to a CAS9 nickase protein and reverse transcriptase construct defined by either a nucleic acid or amino acid sequence encoding such construct. The wild-type prime editor (i.e. having the wild-type Cas9 nickase) is defined by SEQ ID NO. 1 as described in Figure 2, Table A.

[0106] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 1 as described in Figure 2, Table A or a functional fragment thereof.

[0107] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 2 as described in Figure 2, Table A or a functional fragment thereof.

[0108] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%. at least 92%, at least 93%, at leastAttorney Docket No.: 67573-442235VP 1 / 24-010 WO 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 3 as described in Figure 2, Table A or a functional fragment thereof.

[0109] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 4 as described in Figure 2, Table A or a functional fragment thereof.

[0110] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 5 as described in Figure 2, Table A or a functional fragment thereof.

[0111] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 6 as described in Figure 2, Table A or a functional fragment thereof.

[0112] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 7 as described in Figure 2, Table A or a functional fragment thereof.

[0113] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 8 as described in Figure 2, Table A or a functional fragment thereof.

[0114] In another aspect the prime editor described herein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to one of SEQ ID NO. 9 as described in Figure 2, Table A or a functional fragment thereof.

[0115] In one aspect, the prime editor comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NO: 1 - 9.

[0116] In some aspects, any of the prime editors described herein may be co-delivered with one or more of an sgRNA or a pegRNA. sgRNA or pegRNA may be co-delivered in the same vector or a different vector, with the prime editor. The sgRNA provides the guide RNA for anyAttorney Docket No.: 67573-442235VP 1 / 24-010 WO of the Cas9 nickase proteins described herein, while the pegRNA provides the guide RNA for the reverse transcriptase described herein. Collectively, the prime editor, the sgRNA or the pegRNA constitute a “prime editing system” for gene editing and are referred to as such herein.

[0117] Prime “editing efficiency” refers to the measurement of edited DNA as the percentage of amplicons that contain only the desired edit. The “total editing percent (%)” refers to the total edits made, including both the desired edits and any undesired edits (such as indels).

[0118] Prime “editor activity” refers to the desired editing activity. The types of edits may be characterized as: (a) a “precise edit” where the prime editor achieves the desired deletion of one or more nucleotides at one specific position, insertion of one or more nucleotides at one specific position, substitution of a single nucleotide, or other alterations at one specific position to be incorporated into the sequence of the target gene; (b) a “precise edit plus other” where the prime editor achieves the precise edit, but also performs an undesired insertion and / or undesired deletion; or (c) an “imprecise edit” where the prime editor performs an undesired insertion and / or undesired deletion. In some aspects, the prime editor may not perform any editing at all.

[0119] In some aspects the prime editor described herein has at least 1%. at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20% 25%, at least 30%, at least 35%, or at least 40% editing activity as compared to the prime editor comprising SEQ ID NO 1.

[0120] In other aspects, the editing activity comprises a ratio of “precise edits” to “imprecise edits” of about 1 to 1; about 1 to 1.3, about 1 to 1.1 about 1 to 0.75; about 1 to 0.875, about 1 to 0.5; about 1 to 0.33, about 1 to 0.25; about 1 to 0.2, about 1 to 0.15, or about 1 to 0.1. In some aspects, the editing activity comprises a ratio of “precise edits” to “imprecise edits” of about 1 to 0.4.Vectors

[0121] Some aspects of the disclosure are directed to a vector comprising a nucleic acid sequence for any of the Cas9 nickase, fusion proteins or prime editors described herein or a prime editing system described herein. In some aspects, the vector is selected from the group of plasmid vectors, adeno-associated viral vectors, adenovirus vectors, lentiviral vectors, bacteriophage, and virus-like particles. In some embodiments, the vector is an adeno-associated virus. Any suitable vector for packaging the nucleic acids of the Cas9 nickase, the prime editorsAttorney Docket No.: 67573-442235VP 1 / 24-010 WO or prime editing system described herein are contemplated. Vectors may be used to transfect any cells according to methods known in the art.Isolated Cells

[0122] Certain aspects of the current disclosure are directed to an isolated cell comprising any of the Cas9 nickase proteins, fusion proteins or prime editors, prime editing system, or vectors as described herein. In some aspects, the cell may be a normal cell or any diseased or mutant-bearing cell. Cells may be mammalian cells. In some aspect cells may be human cells.

[0123] Such cells may be manipulated to treat a disease, e.g., to correct a mutation, or alter the phenotype of the cell, e.g., to inhibit the growth of a cancer cell, using any of the any of the prime editors and prime editing systems described herein. For example, a cell may be associated with one or more diseases or conditions as described herein.

[0124] In some aspects the cell is a stem cell or progenitor cell (e.g., iPS. embryonic, hematopoietic, adipose, germline, lung, or neural stem or progenitor cells). In some aspects, the manipulated cell may be a cell from any of the three germ layers (e.g., mesodermal, endodermal or ectodermal). In some embodiments, the manipulated cell may be from an extraembryonic tissue, for example, from the placenta. In other aspects, the cell being manipulated may be selected from fibroblasts, monocytic-precursors, B cells, exocrine cells, pancreatic progenitors, endocrine progenitors, hepatoblasts, myoblasts, or preadipocytes. In some embodiments, the cell is manipulated (e.g., converted or differentiated) into muscle cells, erythroid-megakaryocytic cells, eosinophils, iPS cells, macrophages, T cells, islet beta-cells, neurons, cardiomyocytes, blood cells, endocrine progenitors, exocrine progenitors, ductal cells, acinar cells, alpha cells, beta cells, delta cells, PP cells, hepatocytes, cholangiocytes, angioblast, or brown adipocytes.

[0125] In other aspects, the cell is a muscle cell, erythroid-megakaryocytic cell, eosinophil, iPS cell, macrophage, T cell, islet beta-cell, neuron, cardiomyocyte, blood cell, endocrine progenitor, exocrine progenitor, ductal cell, acinar cell, alpha cell, beta cell, delta cell, PP cell, hepatocyte, cholangiocyte, or white or brown adipocyte.

[0126] In other aspects, the cell is a precursor cell, a pluripotent cell, a totipotent cell, an adult stem cell, an inner cell mass cell, an embryonic stem cell, or an iPS cell.

[0127] In other aspects, the manipulated cell is a cancer cell. In some embodiments, the cancer cell can be a lung cancer cell, a breast cancer cell, a skin cancer cell, a brain cancer cell, a pancreatic cancer cell, a hematopoietic cancer cell, a liver cancer cell, a kidney cancer cell, anAttorney Docket No.: 67573-442235VPV24-010 WO ovarian cancer cell, a prostate cancer cell, a skin cancer cell. In some embodiments, the cell is a muscle cell, erythroid-megakaryocytic cell, eosinophil, iPS cell, macrophage, T cell, islet betacell, neuron, cardiomyocyte, blood cell, endocrine progenitor, exocrine progenitor, ductal cell, acinar cell, alpha cell, beta cell, delta cell, PP cell, hepatocyte, cholangiocyte, or white or brown adipocyte.Methods

[0128] Other aspects of the present disclosure describe methods of using any of the engineered Cas9 nickase proteins, fusion proteins or prime editors, prime editor systems, vectors or cells described herein.

[0129] One aspect is a method of cleaving a target nucleic acid in a cell comprising contacting a cell with a vector comprising a nucleic acid encoding any of the Cas9 nickase proteins, prime editors, prime editor systems described herein.

[0130] Another aspect is a method of altering the expression of a target nucleic acid in a cell comprising contacting a cell with a vector comprising a nucleic acid encoding any of the Cas9 nickase proteins, prime editors, or prime editor systems described herein.

[0131] Another aspect is a method of modifying a target nucleic acid in a cell comprising contacting a cell with a vector comprising a nucleic acid encoding any of the Cas9 nickase proteins, prime editors, prime editor systems described herein.

[0132] In some aspects the cells are eukaryotic cells. In other aspects the cells are human cells. In some aspects, the method is in vitro, in other aspects the method is performed in vivo.

[0133] In yet another aspect is a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject any of the engineered Cas9 nickase proteins, prime editors, prime editor systems, vectors or isolated cells as described herein.

[0134] In some aspects, the subject is a patient. In other aspects the subject is human.

[0135] In other aspects, the disease or disorder may be any disease or disorder, including, but not limited to, inherited diseases or disorders or cancer.Alternative Embodiments

[0136] Embodiment 1. An engineered, Cas9 nickase comprising a deletion of one or more amino acid residues in an HNH domain comprising the amino acid sequence of SEQ ID NO. 12.

[0137] Embodiment 2. The Cas9 nickase of embodiment 1, wherein the deletion is about 70%, about 80%, about 90%, or about 95% of the HNH domain of SEQ ID NO. 12.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0138] Embodiment 3. The Cas9 nickase of embodiment 1, wherein the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids, or about 125 amino acids, or more from the HNH domain of SEQ ID NO. 12.

[0139] Embodiment 4. The Cas9 nickase of embodiment 1, wherein the deletion is from about amino acid residues 1 to about 120, about amino acid residues 1 to about 129, about amino acid residues 3 to about 116, about amino acid residues 3 to about 120, about amino acid residues 14 to about 115, or about amino acid residues 17 to about 129 of SEQ ID NO. 12.

[0140] Embodiment 5. The Cas9 nickase of embodiments 1-4, wherein the entire HNH domain is removed.

[0141] Embodiment 6. The Cas9 nickase of any one of the preceding embodiments, derived from Streptococcus pyogenes.

[0142] Embodiment 7. The Cas9 nickase of any one of the preceding embodiments, comprising a first linker between the HNH domain and the RuvC II domain, wherein the first linker has an amino acid sequence of SEQ ID NO: 10.

[0143] Embodiment 8. The Cas9 nickase of embodiment 7, wherein the first linker between the HNH domain and the RuvCII domain is truncated.

[0144] Embodiment 9. The Cas9 nickase of embodiment 8, wherein the first linker truncation is at amino acid 12 or at amino acids 5 to 12 of SEQ ID NO: 10.

[0145] Embodiment 10. The Cas9 nickase of any one of the preceding embodiments, comprising a second linker between the HNH domain and the RuvC III domain, said second linker having an amino acid sequence of SEQ ID NO: 11.

[0146] Embodiment 11. The Cas9 nickase of embodiment 10, wherein the second linker between the HNH domain and the RuvC III domain is truncated.

[0147] Embodiment 12. The Cas9 nickase of embodiment 11, wherein the second linker truncation is at amino acid 1 or at amino acids 1 to 13 of SEQ ID NO. 11.

[0148] Embodiment 13. The Cas9 of any one of the preceding embodiments, wherein the Cas9 retains RuvC nickase activity.

[0149] Embodiment 14. A prime editor comprising: the Cas9 of any one of the preceding claims, and a reverse transcriptase sequence.

[0150] Embodiment 15. The prime editor of embodiment 14, wherein the reverse transcriptase is derived from Moloney Murine Leukemia virusAttorney Docket No.: 67573-442235VPV24-010 WO

[0151] Embodiment 16. The prime editor of embodiment 14 comprising an amino acid sequence at least 80% identical to(a) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGGGLSELDKAGFIKRQLVETRQI TKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNF FKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGF SKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKEL LGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGN ELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADA NLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNI EDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQL TWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRA LLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALG LPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAttorney Docket No.: 67573-442235VPV24-010 WO AVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFG PVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEG QRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVK LD (SEQ ID NO: 2);(b) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYL NAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKT EITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKE SILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGIT IMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELA LPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANL DKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI HQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDE YRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMS QEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHP TVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTAttorney Docket No.: 67573-442235VPV24-010 WO RLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQT LGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFL GKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLT KPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVA LNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKA GAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIH GEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQ AARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD(SEQ ID NO: 3);(c) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKITQRKFDNLTKAERGGLSELDKAGF IKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNI VKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRM LASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQI SEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKAttorney Docket No.: 67573-442235VPV24-010 WO RYTSTKEVLDATLIHQSITGLYETRIDITQRLSQLGGDSGGSSGGSKRTADGSEFESPKKK RKVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAP LIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTND YRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPL FAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLL LAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEAR KETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKA YQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDP VAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMT HYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDA DHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEG KKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCP GHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKK KRKVGSGPAAKRVKLD (SEQ ID NO: 4);(d) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQI LDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPAttorney Docket No.: 67573-442235VPV24-010 WO KRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIME RSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPS KYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKV LSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRL HETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQE ARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTV PNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRL PQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLG NLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG KAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTK PFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTK DAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVAL NPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAG AAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHG EIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQA ARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 5);(e) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHAttorney Docket No.: 67573-442235VPV24-010 WO KPENIVIEMARENQTTQKGQKNSRTQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQIT KHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFF KTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELL GITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADA NLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNI EDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQL TWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRA LLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALG LPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAI AVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFG PVVALNP ATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPD ADHTWYTDGS S LLQEG QRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVK LD (SEQ ID NO: 6);(f) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEAttorney Docket No.: 67573-442235VPV24-010 WO YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRM NTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALI KKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIR KRPLIETNGETGEIVWDKGRDFATVRKVLS MPQ VNIVKKTE VQTGGFS KES ILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKN PIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLY LASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETR IDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRLHETSKEP DVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPH IQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLS GLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSP TLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRAS AKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLF IPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDE KQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTM GQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPL PEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTET EVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRG WLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAI TETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 7); or(g) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDAttorney Docket No.: 67573-442235VPV24-010 WO NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIRE VKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYG DYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEI VWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKK YGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSG GSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSD FPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVP CQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTV LDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDL ADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQV KYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPL YPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLT QKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHA VEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLD ILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAG TSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNK DEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENS SPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 8).

[0152] Embodiment 17. A system comprising the prime editor of any one of embodiments 14-16, wherein the system further comprises a sgRNA.Attorney Docket No.: 67573-442235VPV24-010 WO

[0153] Embodiment 18. The system of embodiment 17, further comprising a pegRNA.

[0154] Embodiment 19. A nucleic acid encoding the Cas9 nickase of embodiments 1-13, or the prime editor of embodiments 14-16.

[0155] Embodiment 20. The nucleic acid of embodiment 19, wherein the nucleic acid is codon-optimized for expression in mammalian cells.

[0156] Embodiment 21. The nucleic acid of embodiment 19, wherein the nucleic acid is codon-optimized for expression in human cells.

[0157] Embodiment 22. A eukaryotic cell comprising the Cas9 nickase of embodiments 1-13, the prime editor of embodiments 14-16 or the system of embodiments 17-18.

[0158] Embodiment 23. The eukaryotic cell of embodiment 22, wherein the cell is a human cell.

[0159] Embodiment 24. A method of cleaving a target nucleic acid in a eukaryotic cell comprising:contacting the cell with the Cas9 nickase of any one of embodiments 1-13, or the prime editor of embodiments 14-16, or the system of embodiments 18-19; andwherein the Cas9 nickase, the prime editor or system is capable of causing a break in the target nucleic acid sequence.

[0160] Embodiment 25. The method of embodiment 24, wherein the break is single stranded break.

[0161] Embodiment 26. A method of altering expression of a target nucleic acid in a eukaryotic cell comprising:contacting the cell with the system of embodiments 17-18;wherein the prime editor is capable of binding to and editing the target nucleic acid sequence.

[0162] Embodiment 27. A method of modifying a target nucleic acid in a eukaryotic cell comprising;contacting the cell with the system of claims 17-18; andwherein the prime editor is capable of binding to and editing the target nucleic acid sequence.

[0163] Embodiment 28. A method of any one of embodiments 24-27, wherein the Cas9 is operably linked to a promoter sequence for expression in a eukaryotic cell, and wherein theAttorney Docket No.: 67573-442235VP 1 / 24-010 WO reverse transcriptase is operably linked to a promoter sequence for expression in a eukaryotic cell.

[0164] Embodiment 29. The method of embodiment 28, wherein the eukaryotic cell is a human cell.

[0165] Embodiment 30. The method of embodiment 29, wherein the promoter sequence is a eukaryotic or viral promoter.

[0166] Embodiment 31. A vector comprising the Cas9 of any one of embodiments 1-13, the prime editor of embodiments 14-16 or the system of claims 17-18.

[0167] Embodiment 32. The vector of embodiment 31, wherein the vector is a plasmid vector or a viral vector.

[0168] Embodiment 33. The vector of embodiment 32, wherein the viral vector is an adeno associated virus (AAV) vector or a lentiviral vector.

[0169] Embodiment 34. A method of treating a disorder or a disease in a subject in need thereof, the method comprising administering to the subject the system of any one of embodiments 17-18.

[0170] Embodiment 35. A method of treating a disorder or a disease in a subject in need thereof, the method comprising administering to the subject a Cas9 nickase comprising a deletion of about 90 amino acids, about 100 amino acids, about 110 amino acids, or 120 amino acids, or more from an HNH domain comprising SEQ ID NO. 12.

[0171] Embodiment 36. The method of embodiment 35, wherein the deletion is about 70%, about 80%, about 90%, or about 95% of the HNH domain of SEQ ID NO. 12.

[0172] Embodiment 37. The method of embodiment 36, wherein the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids, or about 125 amino acids, or more from the HNH domain of SEQ ID NO. 12.

[0173] Embodiment 38, The method of embodiment 35, wherein the deletion is from about amino acid residues 1 to about 120, about amino acid residues 1 to about 129, about amino acid residues 3 to about 116, about amino acid residues 3 to about 120, about amino acid residues 14 to about 115, or about amino acid residues 17 to about 129 of SEQ ID NO. 12.

[0174] Embodiment 39. The method of embodiment 35, wherein the entire HNH domain is removed.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO

[0175] Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this disclosure that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The following examples are provided by way of illustration only and not by way of limitation. Those skilled in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.Attorney Docket No.: 67573-442235VPV24-010 WO EXAMPLESExample 1: Design of HNH deletions

[0176] Visual inspection of the crystal structure of catalytically-active Streptococcus pyogenes CRISPR-Cas9 (SpCas9) in complex with single-guided RNA and double- stranded DNA primed for target DNA cleavage (PDB 5F9R, Jiang et al., 2016) suggested multiple residues which were in spatial proximity to each other on either end of the HNH domain (Figure 1).

[0177] HNH domain deletions were designed to preserve the proximity of these residues and the critical L2 or LI & L2 loops. The Cas9 constructs with HNH deletions are described in Figure 2 Table A. Localcolabfold (https: / / github.com / YoshitakaMo / localcolabfold) was used to predict the structure of each of the truncated constructs. Predictions were aligned to reference structure 5F9R and assessed for structural preservation of the backbone, suggesting the removal of the domain preserves the overall fold necessary to bind nucleic acids in a similar way.Example 2: Cloning and Transfection of ConstructsCell Culture and Transfection

[0178] HEK293-FT cells were thawed and cultured in complete culture medium consisting of high glucose Dulbecco’s Modified Eagle Medium (Thermo Fisher Scientific), with GlutaMAX™ supplement (Thermo Fisher Scientific) and pyruvate, with 10% heat inactivated fetal bovine serum in a T75 flask. When cells reached 80-100% confluency, cells were seeded into 12-well plates, at a concentration of 200,000 cells per 1 mL of complete media in each well. 24 hours after seeding, cells were transfected using the Lipofectamine™ 3000 Transfection kit (Thermo Fisher Scientific), following the manufacturer’s instructions. 3 separate plasmids were transfected simultaneously: 750 ng of RT Editor plasmid. 250 ng of RT-gRNA plasmid, and 83 ng of nicking guide plasmid. The RT Editor plasmid contained a P2A GFP tag, enabling cell sorting for cells that received the editor. Transfection mixes containing the 3 plasmids with P3000, Lipofectamine 3000, and Opti-MEM (Thermo Fisher Scientific) were incubated for 15 minutes at room temperature. After the incubation, 100 pL of the transfection mix was then added directly to the seeded cells.Attorney Docket No.: 67573-442235VPV24-010 WO Example 3: RT Editing Capabilities

[0179] HEK293FT cells were transfected with a 9:3:1 ratio of plasmids expressing RT editor, RT-gRNA:GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCT AGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTG CTCAGTCTG(SEQ ID NO: 13). andngRNA GTCAACCAGTATCCCGGTGCGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCT AGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCC(SEQ ID NO: 14).eGFP was co-translationally expressed with the RT editors through a 2A-eGFP linker. 72 hours after plasmid transfection, cell sorting was performed to collect GFP-positive cells, followed by cell lysis. For each sample, gDNA was extracted, and the genomic site of interest (SEQ ID NO: 15) was amplified, barcoded, and sequenced on an Illumina MiSeq instrument, as described below. Editing was analyzed computationally using VOnTarget (v3.0.1). VOnTarget (v3.0.1), a computational tool developed at Vertex Pharmaceuticals, was used to characterize and quantify on-target editing from the Illumina sequencing data. The output from this analysis was used to generate a summary table shown in Figure 2 and a barplot with percentage of total editing and a breakdown of editing events shown in Figure 3. Editing events were divided into in three categories: (i) precise edit, (ii) precise edit plus additional modifications, and (iii) imprecise edit and measured using next-generation sequencing.Cell Sorting and DNA Extraction

[0180] Seventy-two hours post transfection, cells were harvested and sorted for GFP positive fluorescence with the Sony SH800 cell sorter. 50,000 cells for each sample were collected in 1.5 mL Eppendorf tubes. Cells were pelleted and DNA was extracted using the Maxwell® RSC Blood DNA Kit (Promega Corp.) on the Maxwell® RSC48 (Promega Corp.) according to the manufacturer’s protocol. Extracted DNA was then quantified and normalized to 5 ng / pL using theAttorney Docket No.: 67573-442235VPV24-010 WO Qubit lx dsDNA HS quantification kit (Thermo Fisher Scientific), according to the manufacturer’s protocol.Amplification ofDNA (PCR 1 )

[0181] In a 96-well plate, 25 ng of each DNA sample was added and amplified with 0.5 pM of HEK3 forward primer, 0.5 pM of HEK3 reverse primer and Q5 Hot-Start High Fidelity Master Mix (primers in Table 2 and conditions in Table 3). The PCR products were next purified with AMPure XP beads (Beckman Coulter). The efficacy of amplification was verified via TapeStation 4200 (Agilent) with the D1000 ScreenTape kit (Agilent) according to the manufacturer’ s protocol.Table 2: PCR 1 Primers (NGS)Primer NameSequence(SEQ ID NO )HEK3 Forward TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTGCCTAGAAAGG (SEQ ID NO: 16) CATGGAHEK3 Reverse GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTGTTGAGCTCGA(SEQ ID NO: 15) CCCTGATable 3: PCR 1 Thermal Cycling ConditionsStep Temperature Time Cycles Initial Denaturation 95°C 3 minutes 1 Denaturation 95°C 30 secondsAnnealing 64°C 30 seconds 30 Extension 72°C 45 secondsFinal Extension 72°C 5 minutes 1Hold 4°C Hold N / AAmplification and Barcoding of PCR 1 Products (PCR 2)

[0182] In a 96-well plate, 4 pL of each PCR 1 product was amplified with 0.5 pM of i5 primer, 0.5 pM of i7_N0X primer and Q5® Hot-Start High Fidelity Master Mix (New England Biolabs) (primers in Table 4 and conditions in Table 5). Each i7_N0X primer contained a unique Illumina adapter sequence, allowing for both amplification and barcoding of the individual PCR2 products. The PCR products were next purified with AMPure XP beads (Beckman Coulter). Amplification of the PCR2 products was confirmed using the Qubit lx HS dsDNA Assay Kit on the Qubit 4 Fluorometer (Thermo Fisher Scientific) according to the manufacturer’s protocol. The efficacy of amplification was verified via TapeStation 4200 (Agilent Technologies) with the D1000Attorney Docket No.: 67573-442235VP 1 / 24-010 WO ScreenTape kit (Agilent Technologies) according to the manufacturer’s protocol. Each sample was normalized to 10 ng / pL and equal volume of each sample was combined to produce a completed NGS library.Table 4: PCR 2 Primers (NGS)Primer NameSequence(SEQ ID NO: )i5_UDP0002 AATGATACGGCGACCACCGAGATCTACACCTACAAGATATCGTCGGCAGC (SEQ ID NO: 18) GTCi7_UDP0001(SEQ ID NO: 19) CAAGCAGAAGACGGCATACGAGATCGCTCAGTTCGTCTCGTGGGCTCGG i7_UDP0002(SEQ ID NO: 20) CAAGCAGAAGACGGCATACGAGATTATCTGACCTGTCTCGTGGGCTCGG i7_UDP0003(SEQ ID NO: 21) CAAGCAGAAGACGGCATACGAGATATATGAGACGGTCTCGTGGGCTCGG i7_UDP0004(SEQ ID NO: 22) CAAGCAGAAGACGGCATACGAGATCTTATGGAATGTCTCGTGGGCTCGG i7_UDP0005(SEQ ID NO: 23) CAAGCAGAAGACGGCATACGAGATTAATCTCGTCGTCTCGTGGGCTCGG i7_UDP0006(SEQ ID NO: 24) CAAGCAGAAGACGGCATACGAGATGCGCGATGTTGTCTCGTGGGCTCGG i7_UDP0007(SEQ ID NO: 25) CAAGCAGAAGACGGCATACGAGATAGAGCACTAGGTCTCGTGGGCTCGG i7_UDP0008(SEQ ID NO: 26) CAAGCAGAAGACGGCATACGAGATTGCCTTGATCGTCTCGTGGGCTCGG i7_UDP0009(SEQ ID NO: 27) CAAGCAGAAGACGGCATACGAGATCTACTCAGTCGTCTCGTGGGCTCGG i7_UDP0010(SEQ ID NO: 28) CAAGCAGAAGACGGCATACGAGATTCGTCTGACTGTCTCGTGGGCTCGG i7_UDP0011(SEQ ID NO: 29) CAAGCAGAAGACGGCATACGAGATGAACATACGGGTCTCGTGGGCTCGG i7_UDP0012(SEQ ID NO: 30) CAAGCAGAAGACGGCATACGAGATCCTATGACTCGTCTCGTGGGCTCGG i7_UDP0013(SEQ ID NO: 31) CAAGCAGAAGACGGCATACGAGATTAATGGCAAGGTCTCGTGGGCTCGG i7_UDP0014(SEQ ID NO: 32) CAAGCAGAAGACGGCATACGAGATGTGCCGCTTCGTCTCGTGGGCTCGG i7_UDP0015(SEQ ID NO: 33) CAAGCAGAAGACGGCATACGAGATCGGCAATGGAGTCTCGTGGGCTCGG i7_UDP0016(SEQ ID NO: 34) CAAGCAGAAGACGGCATACGAGATGCCGTAACCGGTCTCGTGGGCTCGG i7_UDP0017(SEQ ID NO: 35) CAAGCAGAAGACGGCATACGAGATAACCATTCTCGTCTCGTGGGCTCGG i7_UDP0018(SEQ ID NO: 36) CAAGCAGAAGACGGCATACGAGATGGTTGCCTCTGTCTCGTGGGCTCGG i7_UDP0019(SEQ ID NO: 37) CAAGCAGAAGACGGCATACGAGATCTAATGATGGGTCTCGTGGGCTCGG i7_UDP0020 CAAGCAGAAGACGGCATACGAGATTCGGCCTATCGTCTCGTGGGCTCGGAttorney Docket No.: 67573-442235VPV24-010 WO (SEQ ID NO: 38)i7_UDP0021(SEQ ID NO: 39) CAAGCAGAAGACGGCATACGAGATAGTCAACCATGTCTCGTGGGCTCGG i7_UDP0022(SEQ ID NO: 40) CAAGCAGAAGACGGCATACGAGATGAGCGCAATAGTCTCGTGGGCTCGG i7_UDP0023(SEQ ID NO: 41) CAAGCAGAAGACGGCATACGAGATAACAAGGCGTGTCTCGTGGGCTCGG i7_UDP0024CAAGCAGAAGACGGCATACGAGATGTATGTAGAAGTCTCGTGGGCTCGG(SEQ ID NO: 42)Table 5: PCR 2 Thermal Cycling ConditionsStep Temperature Time Cycles Initial Denaturation 95°C 3 minutes 1 Denaturation 95°C 30 secondsAnnealing 66°C 30 seconds 10 Extension 72°C 1 minuteFinal Extension 72°C 5 minutes 1Hold 4°C Hold N / ALibrary Loading and Next-Generation Sequencing

[0183] The completed library was diluted to 10 ng / pL and denatured using 0.2 N NaOH and incubated at room temperature for five minutes. The denatured library was diluted to 10 pM using HT1 buffer provided in the MiSeq Reagent Kit v3 (600-cycle) (Illumina). A PhiX Control (Illumina) v3 library was diluted alongside the library of pooled PCR 2 products. The PhiX library was first diluted from 10 nM to the 4 nM using IDTE IX TE Solution pH 8.0, and then denatured using 0.2 N NaOH and incubated at RT for 5 minutes. The denatured PhiX library was further diluted to 10 pM using HT1 buffer provided in the MiSeq Reagent Kit v3 (600-cycle).

[0184] 480 pL of sample library and 120 pL of diluted PhiX library were combined to generate a library containing 20% PhiX. To ensure complete denaturation, the library was incubated at 96°C for 2 minutes and then placed on ice for 5 minutes. The library was then immediately loaded onto the reagent cartridge from a MiSeq Reagent Kit v3 (600-Cycle) and run on the MiSeq Illumina instrument.

[0185] The present disclosure enables one of skill in the relevant art to make and use the inventions provided herein in accordance with multiple and varied embodiments. Various alterations, modifications, and improvements of the present disclosure that readily occur to thoseAttorney Docket No.: 67573-442235VP 1 / 24-010 WO skilled in the art, including certain alterations, modifications, substitutions, and improvements are also part of this disclosure. Accordingly, the foregoing description are by way of example to illustrate the discoveries provided herein. Furthermore, the foregoing Description and Examples are exemplary of the present invention and not limiting thereof. The scope of the invention is therefore set out in the appended claims.

[0186] Although specific embodiments of the present disclosure are herein illustrated and described in detail, the disclosure is not limited thereto. The above detailed descriptions are provided as exemplary of the present disclosure and should not be construed as constituting any limitation of the disclosure. Modifications will be obvious to those skilled in the art, and all modifications that do not depart from the spirit of the disclosure are intended to be included with the scope of the appended claims.

Claims

Attorney Docket No.: 67573-442235VP 1 / 24-010 WO CLAIMS1. An engineered, Cas9 nickase comprising a deletion of one or more amino acid residues in an HNH domain comprising the amino acid sequence of SEQ ID NO. 12.

2. The Cas9 nickase of claim 1, wherein the deletion is about 70%, about 80%, about 90%, or about 95% of the HNH domain of SEQ ID NO. 12.

3. The Cas9 nickase of claim 1, wherein the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids, or about 125 amino acids, or more from the HNH domain of SEQ ID NO. 12.

4. The Cas9 nickase of claim 1, wherein the deletion is from about amino acid residues 1 to about 120, about amino acid residues 1 to about 129, about amino acid residues 3 to about 116, about amino acid residues 3 to about 120, about amino acid residues 14 to about 115, or about amino acid residues 17 to about 129 of SEQ ID NO. 12.

5. The Cas9 nickase of claims 1-4, wherein the entire HNH domain is removed.

6. The Cas9 nickase of any one of the preceding claims, derived from Streptococcus pyogenes.

7. The Cas9 nickase of any one of the preceding claims, comprising a first linker between the HNH domain and the RuvC II domain, wherein the first linker has an amino acid sequence of SEQ ID NO: 10.

8. The Cas9 nickase of claim 7, wherein the first linker between the HNH domain and the RuvCII domain is truncated.

9. The Cas9 nickase of claim 8. wherein the first linker truncation is at amino acid 12 or at amino acids 5 to 12 of SEQ ID NO: 10.

10. The Cas9 nickase of any one of the preceding claims, comprising a second linker between the HNH domain and the RuvC III domain, said second linker having an amino acid sequence of SEQ ID NO: 11.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO 11. The Cas9 nickase of claim 10, wherein the second linker between the HNH domain and the RuvC III domain is truncated.

12. The Cas9 nickase of claim 11, wherein the second linker truncation is at amino acid 1 or at amino acids 1 to 13 of SEQ ID NO. 11.

13. The Cas9 of any one of the preceding claims, wherein the Cas9 retains RuvC nickase activity.

14. A prime editor comprising: the Cas9 of any one of the preceding claims, and a reverse transcriptase sequence.

15. The prime editor of claim 14, wherein the reverse transcriptase is derived from Moloney Murine Leukemia virus16. The prime editor of claim 14 comprising an amino acid sequence at least 80% identical to (a) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHS1KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNR1CYLQE1FSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGGGLSELDKAGFIKRQLVETRQI TKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHD AYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNF FKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFAttorney Docket No.: 67573-442235VPV24-010 WO SKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKEL LGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGN ELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADA NLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNI EDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQL TWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRA LLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALG LPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAI AVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFG PVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEG QRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVK LD (SEQ ID NO: 2);(b) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHAttorney Docket No.: 67573-442235VPV24-010 WO KPENIVIEMARENQTTQKGQKNSRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYL NAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKT EITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKE SILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGIT IMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELA LPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANL DKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLI HQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDE YRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMS QEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHP TVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWT RLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQT LGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFL GKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLT KPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVA LNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKA GAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIH GEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQ AARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD(SEQ ID NO: 3);(c) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEAttorney Docket No.: 67573-442235VPV24-010 WO YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKITQRKFDNLTKAERGGLSELDKAGF IKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNI VKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRM LASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQI SEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK RYTSTKEVLDATLIHQSITGLYETRIDITQRLSQLGGDSGGSSGGSKRTADGSEFESPKKK RKVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAP LIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTND YRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPL FAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLL LAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEAR KETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKA YQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDP VAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMT HYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDA DHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEG KKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCP GHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKK KRKVGSGPAAKRVKLD (SEQ ID NO: 4);(d) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDAttorney Docket No.: 67573-442235VPV24-010 WO NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQI LDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILP KRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIME RSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPS KYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKV LSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRL HETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQE ARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTV PNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRL PQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLG NLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG KAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTK PFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTK DAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVAL NPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAG AAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHG EIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQA ARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 5);Attorney Docket No.: 67573-442235VPV24-010 WO (e) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRTQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQIT KHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFF KTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFS KESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELL GITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADA NLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNI EDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQL TWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRA LLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALG LPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAI AVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFG PVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGAttorney Docket No.: 67573-442235VPV24-010 WO QRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVK LD (SEQ ID NO: 6);(f) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQTTQKGQKNSRERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRM NTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALI KKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIR KRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKN PIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLY LASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETR IDLSQLGGDSGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRLHETSKEP DVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPH IQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLS GLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSP TLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRAS AKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFAttorney Docket No.: 67573-442235VPV24-010 WO IPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDE KQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTM GQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPL PEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTET EVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRG WLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAI TETPDTSTLLIENSSPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 7); or(g) MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVL GNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYL ALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLKRE DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYE YFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLK TYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRH KPENIVIEMARENQGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIRE VKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYG DYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEI VWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKK YGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENI IHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSG GSSGGSKRTADGSEFESPKKKRKVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSD FPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPAttorney Docket No.: 67573-442235VP 1 / 24-010 WO CQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTV LDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDL ADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQV KYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPL YPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLT QKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHA VEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLD ILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAG TSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNK DEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENS SPSGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 8).

17. A system comprising the prime editor of any one of claims 14-16, wherein the system further comprises a sgRNA.

18. The system of claim 17, further comprising a pegRNA.

19. A nucleic acid encoding the Cas9 nickase of claims 1-13, or the prime editor of claims 14-16.

20. The nucleic acid of claim 19, wherein the nucleic acid is codon-optimized for expression in mammalian cells.

21. The nucleic acid of claim 19, wherein the nucleic acid is codon-optimized for expression in human cells.

22. A eukaryotic cell comprising the Cas9 nickase of claims 1-13, the prime editor of claims 14-16 or the system of claims 17-18.

23. The eukaryotic cell of claim 22, wherein the cell is a human cell.

24. A method of cleaving a target nucleic acid in a eukaryotic cell comprising:contacting the cell with the Cas9 nickase of any one of claims 1-13, or the prime editor of claims 14-16. or the system of claims 17-18: andAttorney Docket No.: 67573-442235VP 1 / 24-010 WO wherein the Cas9 nickase, the prime editor or system is capable of causing a break in the target nucleic acid sequence.

25. The method of claim 24, wherein the break is single stranded break.

26. A method of altering expression of a target nucleic acid in a eukaryotic cell comprising:contacting the cell with the system of claims 17-18;wherein the prime editor is capable of binding to and editing the target nucleic acid sequence.

27. A method of modifying a target nucleic acid in a eukaryotic cell comprising:contacting the cell with the system of claims 17-18; andwherein the prime editor is capable of binding to and editing the target nucleic acid sequence.

28. A method of any one of claims 24-27, wherein the Cas9 is operably linked to a promoter sequence for expression in a eukaryotic cell, and wherein the reverse transcriptase is operably linked to a promoter sequence for expression in a eukaryotic cell.

29. The method of claim 28, wherein the eukaryotic cell is a human cell.

30. The method of claim 28, wherein the promoter sequence is a eukaryotic or viral promoter.

31. A vector comprising the Cas9 of any one of claims 1-13, the prime editor of claims 14-16 or the system of claims 17-18.

32. The vector of claim 31, wherein the vector is a plasmid vector or a viral vector.

33. The vector of claim 31, wherein the viral vector is an adeno associated virus (AAV) vector or a lentiviral vector.

34. A method of treating a disorder or a disease in a subject in need thereof, the method comprising administering to the subject the system of any one of claims 17-18.Attorney Docket No.: 67573-442235VP 1 / 24-010 WO 35. A method of treating a disorder or a disease in a subject in need thereof, the method comprising administering to the subject a Cas9 nickase comprising a deletion of about 90 amino acids, about 100 amino acids, about 110 amino acids, or 120 amino acids, or more from an HNH domain comprising SEQ ID NO. 12.

36. The method of claim 35, wherein the deletion is about 70%, about 80%, about 90%, or about 95% of the HNH domain of SEQ ID NO. 12.

37. The method of claim 35, wherein the deletion removes about 90 amino acids, about 100 amino acids, about 110 amino acids, or about 125 amino acids, or more from the HNH domain of SEQ ID NO. 12.

38. The method of claim 35, wherein the deletion is from about amino acid residues 1 to about 120, about amino acid residues 1 to about 129, about amino acid residues 3 to about 116, about amino acid residues 3 to about 120, about amino acid residues 14 to about 115, or about amino acid residues 17 to about 129 of SEQ ID NO. 12.

39. The method of claim 35, wherein the entire HNH domain is removed.